Galapagos revives dropped cachexia drug

Belgian drug discovery firm Galapagos has selected a small-molecule candidate that it had previously abandoned to enter into preclinical  development in the treatment of cachexia, now bioavailability problems  have been overcome.

G100192 binds to targeted androgen receptors, potentially enabling the  drug to be efficacious without the cardiovascular, prostate or virility  side effects traditionally seen in androgen therapies. The firm is  aiming for once-a-day oral dosing with a possible second indication in  osteoporosis.